Shots:

• Pheast Therapeutics highlighted new preclinical data of PHST001, an anti-CD24 antibody designed to block a key "don’t eat me" signal on cancer cells, promoting immune response, at SITC 2024
• The poster was entitled as, ‘PHST001, a humanized anti-CD24 antibody, induces phagocytosis of human tumor cells in vitro and tumor clearance in vivo’
• The preclinical data depicted that PHST001 attaches with CD24 and induces macrophage-driven phagocytosis, significantly reducing tumors in vivo and a favorable PK profile without immune-mediated toxicity among non-human primates in vitro. Pheast plans to start clinical trials in H1’25

Ref: Pheast Therapeutics  | Image: Pheast Therapeutics 

Related News:- Macrophage Checkpoint Therapy: Roy Maute from Pheast Therapeutics in a Riveting Conversation with PharmaShots

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com